|1.||Meijers, Joost C M: 11 articles (02/2013 - 01/2002)|
|2.||Morser, John: 10 articles (10/2013 - 01/2002)|
|3.||Taguchi, Osamu: 9 articles (10/2013 - 02/2003)|
|4.||Gabazza, Esteban C: 9 articles (10/2013 - 02/2002)|
|5.||Gils, A: 8 articles (02/2014 - 02/2005)|
|6.||Meijers, J C M: 7 articles (11/2015 - 10/2003)|
|7.||Declerck, Paul J: 7 articles (02/2015 - 02/2006)|
|8.||Gils, Ann: 7 articles (02/2015 - 02/2006)|
|9.||Declerck, P J: 7 articles (02/2014 - 02/2008)|
|10.||Suzuki, Koji: 7 articles (04/2009 - 02/2002)|
02/01/2007 - "Significant reduction in thrombus formation was observed in TAFI(-/-) mice (n = 8, P < 0.05 compared to wild-type littermates) but not in heterozygous (TAFI(+/-)) mice in 3.5% FeCl(3)-induced vena cava thrombosis. "
01/01/2010 - "A suitable inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) has the potential to be a novel treatment for thrombosis. "
03/01/2012 - "Finally, the numerous clinical studies in patients with thrombotic disease support the idea that increased levels of TAFI and/or the enhancement of TAFI activation may represent a new risk factor for venous and arterial thrombosis."
01/01/2010 - "Our study shows that TAFI does not play a major role for thrombus formation and neuronal degeneration after ischemic brain challenge."
06/01/2009 - "The aim of the present study was to elucidate the pathogenetic role of TAFI levels and genotypes in young patients with arterial thrombosis. "
01/01/2014 - "The present study compared efficacy between TAFI inhibition alone and TAFI inhibition in combination with rtPA at a suboptimal dose, in a murine model of thromboembolic stroke. "
05/01/2010 - "Association between the Thr325Ile polymorphism of the thrombin-activatable fibrinolysis inhibitor and stroke in the Ludwigshafen Risk and Cardiovascular Health Study."
01/01/2010 - "In the present study we analyzed stroke development and post stroke functional outcome in TAFI-/- mice. "
04/01/2007 - "The aim of the present study was to investigate the possible association between TAFI and overall ischemic stroke and ischemic stroke subtypes. "
04/01/2003 - "The purpose of this work was to study TAFI levels in the acute phase of ischemic stroke and their relationship with stroke evolution. "
07/01/2001 - "Despite decreased levels of TAFI and other components of the fibrinolytic system, no evidence of increased plasma fibrinolytic potential in cirrhosis is observed using the plasma-based assay of this study. "
01/01/2008 - "Protective role of thrombin activatable fibrinolysis inhibitor in obstructive nephropathy-associated tubulointerstitial fibrosis."
07/01/2003 - "Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis."
07/01/2001 - "TAFI levels were decreased in cirrhosis. "
07/01/2001 - "Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis."
02/01/2013 - "The effect of hypothyroidism on TAFI was studied in a multicentre observational cohort study. "
02/01/2013 - "Thrombin-activatable fibrinolysis inhibitor in hypothyroidism and hyperthyroxinaemia."
10/01/2010 - "The aim of this study was to determine the effects of overt hypothyroidism on the levels of TAFI antigen (TAFI Ag) and TAFI activity (TAFIa). "
02/01/2009 - "Therefore, the main purpose of this study was to evaluate the profile of coagulation and fibrinolytic parameters including TAFI and TFPI in patients with hypothyroidism. "
09/01/2012 - "Increased TAFI and decreased TFPI and TM in patients with hypothyroidism may indicate a potential hypercoagulable and hypofibrinolytic state as well as possible endothelial dysfunction, which may increase the risk of atherosclerotic and atherothrombotic complications. "
09/01/2012 - "Since impaired fibrinolysis is a very well established risk factor for cardiovascular morbidity and mortality, understanding the role of TAFI in cardiovascular disorders, insulin resistance, diabetes and other endocrine problems may hold promise for improving management of these diseases. "
02/01/2005 - "It is supposed that plasma TAFI levels are regulated at least in part by transcription levels in adipose tissues of patients with insulin resistance."
02/01/2005 - "We have reported the elevated levels of plasma TAFI and their correlation with visceral fat area and insulin resistance in the patients with type 2 diabetes. "
02/01/2002 - "Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients."
02/01/2002 - "This study showed that increased circulating level of TAFI may be an important causative factor of hypofibrinolysis in patients with type 2 diabetes, obesity and insulin resistance."
|1.||Carboxypeptidase U (TAFI)
|4.||recombinant FVIIa (rFVIIa)
|6.||lipoprotein-associated coagulation inhibitor (TFPI)
|7.||Plasminogen Activator Inhibitor 1
|8.||Plasminogen Activators (Plasminogen Activator)
|10.||Tissue Plasminogen Activator (Alteplase)
|2.||Hormone Replacement Therapy (Therapy, Hormone Replacement)
|4.||Transplantation (Transplant Recipients)
|5.||Renal Dialysis (Hemodialysis)